Giuseppe Galgano

Bari, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Selexipag in systemic sclerosis-associated pulmonary arterial hypertension: long-term real-world data from a multicentre Italian cohort.

Selexipag in systemic sclerosis-associated pulmonary arterial hypertension: long-term real-world data from a multicentre Italian cohort.

Journal: Rheumatology (Oxford, England)

Published: March 21, 2026

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective.

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective.

Journal: Vascular pharmacology

Published: December 20, 2025

TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension.

TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension.

Journal: Circulation. Heart failure

Published: September 17, 2025

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk score.

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of REVEAL risk score.

Journal: Vascular pharmacology

Published: August 27, 2025

Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.

Pulmonary arterial hypertension: right ventricular phenotyping to improve risk assessment at follow-up.

Journal: European heart journal

Published: May 12, 2025

Value of right heart haemodynamics for risk stratification of patients with pulmonary arterial hypertension at follow-up.

Value of right heart haemodynamics for risk stratification of patients with pulmonary arterial hypertension at follow-up.

Journal: ESC heart failure

Published: April 08, 2025

Utility of Clustering in Mortality Risk Stratification in Pulmonary Hypertension.

Utility of Clustering in Mortality Risk Stratification in Pulmonary Hypertension.

Journal: Bioengineering (Basel, Switzerland)

Published: March 06, 2025

Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus.

Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus.

Journal: Vascular pharmacology

Published: July 06, 2024

Right ventricular phenotyping in incident patients with idiopathic pulmonary arterial hypertension.

Right ventricular phenotyping in incident patients with idiopathic pulmonary arterial hypertension.

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Published: April 12, 2024

Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension.

Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension.

Journal: ERJ open research

Published: June 24, 2022

The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?

The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?

Journal: The European respiratory journal

Published: August 18, 2021

Chronic thromboembolic pulmonary hypertension risk score evaluation and validation (CTEPH SOLUTION): proposal of a study protocol aimed to realize a validated risk score for early diagnosis.

Chronic thromboembolic pulmonary hypertension risk score evaluation and validation (CTEPH SOLUTION): proposal of a study protocol aimed to realize a validated risk score for early diagnosis.

Journal: Minerva cardiology and angiology

Published: March 11, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026